Summary from the 153rd meeting of the American Psychiatric Association. 13-18 May 2000, Chicago, Illinois, USA.
The annual meeting of the American Psychiatric Association focuses on a variety of topics, including those on psychopharmacology. The latest developments are typically those found in the New Research sections, which is where this summary will focus.
Goodnick
P J
PJ
University of Miami, Department of Psychiatry & Behavioural Sciences, Miami, FL, USA. pgoodnick@aol.com
D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001569:Benzodiazepines; D001714:Bipolar Disorder / Q000188:drug therapy; D015283:Citalopram / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy / Q000523:psychology; D006801:Humans; D020902:Hypericum / Q000627:therapeutic use; D000077152:Olanzapine; D008517:Phytotherapy; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010946:Plants, Medicinal; D011570:Psychiatry; D011619:Psychotropic Drugs / Q000494:pharmacology*; D012958:Societies, Scientific; D013739:Testosterone / Q000627:therapeutic use; D014481:United States
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D011619:Psychotropic Drugs; D015283:Citalopram; D001569:Benzodiazepines; D010890:Pirenzepine; D013739:Testosterone; D000077152:Olanzapine